Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Permanent room-temperature storage will degrade the peptide and reduce effectiveness over time
The combination of precise dosing and optimized nutrition produces dramatically better outcomes than medication alone
TerzaPowertirzepatide 60 mg Dual GLP-1/GIP receptor agonist for comprehensive weight management, metabolic balance, and glycemic control GLP-1 + GIP 60 mg max format 1/week A clinical foundation SURMOUNT-1 Weight loss up to 22.5% over 72 weeks in obese patients (15 mg dose) SURPASS-2 Superiority over semaglutide 1 mg in reducing HbA1c and body weight in type 2 diabetes Dual mechanism The only molecule with dual GLP-1/GIP agonism for maximum metabolic effect FDA & EMA FDA-approved (Mounjaro/Zepbound) for obesity and type 2 diabetes treatment Key effects Comprehensive metabolic impact through a dual mechanism of action How TerzaPower Dual activation of GLP-1 and GIP receptors in the GI tract and brain Appetite and hunger reduction through central CNS mechanisms Slowing of gastric emptying prolonged satiety Improvement of glucose-dependent insulin secretion by pancreatic beta cells Reduction of glucagon production and suppression of hepatic gluconeogenesis Activation of adipose tissue lipolysis and increased peripheral insulin sensitivity Why TerzaPower
Nat Med 31 , 31283140 (2025)
